Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
This study has been completed.
Study NCT00034281   Information provided by Takeda Global Research & Development Center, Inc.
First Received: April 24, 2002   Last Updated: December 18, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasm
Pancreatic Neoplasm
Lung Neoplasm
Ovarian Neoplasm
Renal Neoplasm
Additional conditions recognized in this trial
Breast Neoplasms
Kidney Neoplasms
Lung Neoplasms
Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
More general conditions related to this trial
Adnexal Diseases
Breast Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Kidney Diseases
Lung Diseases
Neoplasms by Site
Ovarian Diseases
Pancreatic Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
TAK-165
Sponsors listed in this trial
Takeda Global Research &Development Center, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services